Iter-4360dd15-0105-transcript
第 105 轮执行轨迹
→ call search_memory({"limit":10,"query":"4360dd15 38310895 Europe PMC references PMID 原始试验"}) → call list_recent({"n":8})
→ call list_by_tag({"limit":10,"tag":"4360dd15"})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0097-transcript", "tags": "iteration transcript", "modified": "20260424211821000", "preview": "!! 第 97 轮执行轨迹
→ call search_memory({\"limit\":8,\"query\":\"4360dd15 38310895 参考文献 原始人类试验 PMID mTOR rapalog 主要终点\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0060-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424200117000\", \"preview\": \"!! 第 60 轮执行轨迹 → call search_memory({\"limit\":8,\"query\":\"4360dd15 38310895 Europe PMC references human trial PMID\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0097-transcript\", \"tags\": \"i【tool:list_recent】
{"ok": true, "items": [{"title": "Error-20260425-053356", "modified": "20260424213356000", "tags": "error iteration"}, {"title": "Iter-4360dd15-0103-reflection", "modified": "20260424213353000", "tags": "iteration reflection"}, {"title": "NEXT_FOCUS", "modified": "20260424213353000", "tags": "pinned focus"}, {"title": "先验明响应格式再写解析器", "modified": "20260424213353000", "tags": "lesson evidence-chain parsing europe-pmc"}, {"title": "Iter-4360dd15-0103-transcript", "modified": "20260424213321000", "tags": "iteration transcript"}, {"title": "Iter-4360dd15-0103-EuropePMC-38310895-reference-parser-and-candidate-shortlist", "modified": "20260424213315000", "tags": "knowledge fact method 4360dd15 clinical-trials evidence-chain"}, {"title": "Iter-4360dd15-0102-reflection", "modified": "20260424213132000", "tags": "iteration reflection"}, {"title": "Iter-4360dd15-0102-transcript", "modified": "20260424213124000", "tags": "iteration transcript"}]}
【tool:list_by_tag】
{"ok": true, "items": [{"title": "Iter-4360dd15-0103-EuropePMC-38310895-reference-parser-and-candidate-shortlist", "modified": "20260424213315000"}, {"title": "Iter-4360dd15-0100-human-trial-vs-non-original-screening-of-38310895-references", "modified": "20260424212530000"}, {"title": "Iter-4360dd15-0099-critic-mechanistic-vs-aging-trial", "modified": "20260424212312000"}, {"title": "Iter-4360dd15-0098-EuropePMC-extract-human-trial-PMIDs", "modified": "20260424212055000"}, {"title": "PMID 22367193 is cardiac-repolarization safety, not longevity evidence", "modified": "20260424210833000"}, {"title": "PMID 24691032 is muscle-protein-synthesis endpoint, not longevity evidence", "modified": "20260424210355000"}, {"title": "PMID 22115710 is phase I ocular safety study, not longevity evidence", "modified": "20260424210145000"}, {"title": "PMID 29408453 is feasibility/safety pilot, not direct longevity evidence", "modified": "20260424210012000"}, {"title": "PMID 31761958 is skin-senescence endpoint, not longevity evidence", "modified": "20260424205759000"}, {"title": "PMID 33977284 is RTI incidence endpoint, not direct longevity evidence", "modified": "20260424204839000"}]}
→ call read_note({"title":"NEXT_FOCUS"})
→ call read_note({"title":"Iter-4360dd15-0103-EuropePMC-38310895-reference-parser-and-candidate-shortlist"})
→ call read_note({"title":"Iter-4360dd15-0102-transcript"})
【tool:read_note】
{"ok": true, "title": "NEXT_FOCUS", "tags": "pinned focus", "text": "!! 下轮焦点（来自 mission `4360dd15` · Iter-0103）\n\n下一轮必须先把 PMID 38310895 的 Europe PMC 参考文献稳定解析成 PMID-标题列表。"}
【tool:read_note】
{"ok": true, "title": "Iter-4360dd15-0103-EuropePMC-38310895-reference-parser-and-candidate-shortlist", "tags": "knowledge fact method 4360dd15 clinical-trials evidence-chain", "text": "!! PMID 38310895 的 Europe PMC 参考文献已稳定解析为 PMID-标题列表\n\n这轮把 `https://www.ebi.ac.uk/europepmc/webservices/rest/MED/38310895/references/1/1000` 解析成了结构化列表。\n\n!! 可复现解析方式\n* 返回格式是 XML，根节点为 `responseWrapper`，参考文献节点为 `reference`。\n* 每个 `reference` 里可直接读取：\n** `id` → PMID\n** `title` → 文献标题\n** `authorString` / `journalAbbreviation` / `pubYear` → 辅助信息\n\n!! 最小可复现 Python\n
\n\n!! 这轮的验证结果\n* 总参考文献数：`75`\n* 其中本轮额外锁定的、尚未在旧清单里复核的“看起来像原始人体研究”的候选 PMID 只有 4 条：\n** `19963096` — *Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations.*\n** `24151517` — *Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors.*\n** `30564495` — *Everolimus for treatment-refractory seizures in TSC: Extension of a randomized controlled trial.*\n** `24267730` — *Sa【tool:read_note】
{"ok": true, "title": "Iter-4360dd15-0102-transcript", "tags": "iteration transcript", "text": "!! 第 102 轮执行轨迹\n\n
→ call search_memory({\\\"limit\\\":8,\\\"query\\\":\\\"4360dd15 38310895 rapamycin review original human trial PMID table references\\\"}) → call list_recent({\\\"n\\\":8}) → call list_by_tag({\\\"limit\\\":20,\\\"tag\\\":\\\"4360dd15\\\"}) 【tool:search_memory】 {\\\"ok\\\": true, \\\"results\\\": [{\\\"title\\\": \\\"Iter-4360dd15-0010-transcript\\\", \\\"tags\\\": \\\"iteration transcript\\\", \\\"modified\\\": \\\"20260424175830000\\\", \\\"preview\\\": \\\"!! 第 1\"}, {\"title\": \"Iter-4360dd15-0088-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424205606000\", \"preview\": \"!! 第 88 轮执行轨迹 → call web_fetch({"max_chars":5000,"url":"https://pubmed.ncbi.nlm.nih.gov/19963096/"})
→ call web_fetch({"max_chars":5000,"url":"https://pubmed.ncbi.nlm.nih.gov/24151517/"})
→ call web_fetch({"max_chars":5000,"url":"https://pubmed.ncbi.nlm.nih.gov/30564495/"})
【tool:web_fetch】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://pubmed.ncbi.nlm.nih.gov/19963096/'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
【tool:web_fetch】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://pubmed.ncbi.nlm.nih.gov/24151517/'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
【tool:web_fetch】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://pubmed.ncbi.nlm.nih.gov/30564495/'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
→ call web_search({"limit":5,"query":"\"19963096\" temsirolimus cancer patients clinical pharmacology dosing considerations"})
→ call web_search({"limit":5,"query":"\"24151517\" systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors"})
→ call web_search({"limit":5,"query":"\"30564495\" Everolimus for treatment-refractory seizures in TSC Extension of a randomized controlled trial"})
【tool:web_search】
{"ok": true, "query": "\"19963096\" temsirolimus cancer patients clinical pharmacology dosing considerations", "results": [{"title": "Intravenous temsirolimus in cancer patients: clinical pharmacology and ...", "url": "https://www.wikidata.org/wiki/Q34614538", "snippet": "19963096 3 August 2017 main subject pharmacology 1 reference based on heuristic inferred from title author name string Joseph P Boni series ordinal 1 1 reference stated in PubMed publication ID 19963096 3 August 2017 Bruce Hug series ordinal 2 1 reference stated in PubMed publication ID 19963096 3 August 2017 Cathie Leister series ordinal 3 1 ..."}, {"title": "Temsirolimus. - Abstract - Europe PMC", "url": "https://europepmc.org/article/MED/17987219", "snippet": "Intravenous temsirolimus in cancer patients : clinical pharmacology and dosing considerations . Boni JP, Hug B, Leister C, Sonnichsen D Semin Oncol, 36 Suppl 3:S18-25, 01 Dec 2009 Cited by: 31 articles | PMID: 19963096 Review"}, {"title": "Clinical development of temsirolimus, a novel mTOR inhibitor, for ...", "url": "https://europepmc.org/article/MED/19963095", "snippet": "Intravenous temsirolimus in cancer patients : clinical pharmacology and dosing considerations . Boni JP, Hug B, Leister C, Sonnichsen D Semin Oncol, 36 Suppl 3:S18-25, 01 Dec 2009 Cited by: 28 articles | PMID: 19963096 Review"}, {"title": "Temsirolimus - Wikipedia, wolna encyklopedia", "url": "https://pl.wikipedia.org/wiki/Temsirolimus", "snippet": "Intravenous temsirolimus in ca
【tool:web_search】
{"ok": true, "query": "\"24151517\" systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors", "results": []}
【tool:web_search】
{"ok": true, "query": "\"30564495\" Everolimus for treatment-refractory seizures in TSC Extension of a randomized controlled trial", "results": []}
→ call web_search({"limit":8,"query":"24151517 Europe PMC title mTOR inhibitors renal transplant patients adverse effects review"})
→ call web_search({"limit":8,"query":"30564495 Europe PMC everolimus treatment-refractory seizures TSC extension randomized controlled trial"})
→ call web_search({"limit":8,"query":"19963096 Europe PMC review temsirolimus cancer patients clinical pharmacology dosing considerations"})
【tool:web_search】
{"ok": true, "query": "24151517 Europe PMC title mTOR inhibitors renal transplant patients adverse effects review", "results": [{"title": "Systemic and Nonrenal Adverse Effects Occurring in Renal Transplant ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3789319/", "snippet": "Although the clinical utility of this drug category is clear, as other immunosuppressive drugs, mTOR-I may induce the development of several adverse effects (Table 1) that need to be early recognized and treated to avoid severe illness in renal transplant patients . Table 1. Most common adverse events in mTOR-I-treated renal transplant recipients."}, {"title": "Systemic and nonrenal adverse effects occurring in renal transplant ...", "url": "https://europepmc.org/article/MED/24151517", "snippet": "However, as other immunosuppressive drugs, mTOR-I may induce the development of several adverse effects that need to be early recognized and treated to avoid severe illness in renal transplant patients ."}, {"title": "Calcineurin and mTOR inhibitors in kidney transplantation ... - Springer", "url": "https://link.springer.com/article/10.1007/s11255-023-03754-3", "snippet": "In our study, we examined the efficacy of mTOR (mammalian target of rapamycin) inhibitors , specifically rapamycin (Rap), compared to calcineurin inhibitors (CNIs) in kidney transplantation. By conducting a comprehensive search across reputable databases (EMBASE, Scopus, PubMed, Cochrane, and Crossref), we gathered data for a six-mont
【tool:web_search】
{"ok": true, "query": "30564495 Europe PMC everolimus treatment-refractory seizures TSC extension randomized controlled trial", "results": [{"title": "Everolimus for treatment-refractory seizures in TSC ... - Europe PMC", "url": "https://europepmc.org/article/MED/30564495", "snippet": "EXamining everolimus In a Study of Tuberous sclerosis 3 (EXIST-3) demonstrated significantly reduced seizure frequency (SF) with everolimus vs placebo. In this study, we evaluate the long-term efficacy and safety of everolimus for tuberous sclerosis complex (TSC)-associated treatment-refractory seizures ."}, {"title": "Everolimus for treatment-refractory seizures in TSC", "url": "https://www.neurology.org/doi/10.1212/CPJ.0000000000000514", "snippet": "This interventional study ( extension phase) provides Class IV evidence that a sustained effect was observed with everolimus treatment as an adjunctive therapy for the treatment of refractory seizures associated with TSC ."}, {"title": "Everolimus for treatment-refractory seizures in TSC: Extension of a ...", "url": "https://www.researchgate.net/publication/328287203_Everolimus_for_treatment-refractory_seizures_in_TSC_Extension_of_a_randomized_controlled_trial", "snippet": "In this study, we evaluate the long-term efficacy and safety of everolimus for tuberous sclerosis complex (TSC)-associated treatment-refractory seizures ."}, {"title": "PubMed Central (PMC)", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6276348/", "snippet": "We would like
【tool:web_search】
{"ok": true, "query": "19963096 Europe PMC review temsirolimus cancer patients clinical pharmacology dosing considerations", "results": [{"title": "Intravenous temsirolimus in cancer patients: clinical ... - Europe PMC", "url": "https://europepmc.org/article/MED/19963096", "snippet": "Therefore, temsirolimus dose adjustments are warranted if coadministration cannot be avoided. Despite its complexity, the PK profile of IV temsirolimus is well characterized in cancer patients and provides a strong basis for its future study as a monotherapy or in combination with other anticancer agents."}, {"title": "Intravenous temsirolimus in cancer patients: clinical pharmacology and ...", "url": "https://pubmed.ncbi.nlm.nih.gov/19963096/", "snippet": "Therefore, temsirolimus dose adjustments are warranted if coadministration cannot be avoided. Despite its complexity, the PK profile of IV temsirolimus is well characterized in cancer patients and provides a strong basis for its future study as a monotherapy or in combination with other anticancer agents."}, {"title": "Temsirolimus. - Abstract - Europe PMC", "url": "https://europepmc.org/article/MED/17987219", "snippet": "Intravenous temsirolimus in cancer patients : clinical pharmacology and dosing considerations . Boni JP, Hug B, Leister C, Sonnichsen D Semin Oncol, 36 Suppl 3:S18-25, 01 Dec 2009 Cited by: 31 articles | PMID: 19963096 Review"}, {"title": "Intravenous Temsirolimus in Cancer Patients: Clinical Pharmacology and ...", "url": "h
→ call web_fetch({"max_chars":3500,"url":"https://europepmc.org/article/MED/24151517"})
→ call web_fetch({"max_chars":3500,"url":"https://europepmc.org/article/MED/30564495"})
→ call web_fetch({"max_chars":3500,"url":"https://europepmc.org/article/MED/19963096"})
【tool:web_fetch】
{"ok": true, "url": "https://europepmc.org/article/MED/24151517", "status": 200, "content_type": "text/html;charset=UTF-8", "text": "Europe PMC Europe PMC 1 Sign in | Create an account https://orcid.org https://plus.europepmc.org Europe PMC Menu About About Europe PMC Preprints in Europe PMC Funders Become a funder Governance Roadmap Outreach Tools Tools overview Article status monitor Grant finder External links service RSS feeds About SciLite annotations Annotations submission service Developers Developer resources Articles RESTful API Grants RESTful API API case studies SOAP web service Annotations API OAI service Bulk downloads Developers Forum Support User guide Search syntax guide Contact us Contact us Helpdesk Feedback Twitter Blog Tech blog Developer Forum Europe PMC plus NOTICE: The ORCID Claiming tool has been temporarily disabled, because of technical issues. Please check back in later.", "truncated": false}
【tool:web_fetch】
{"ok": true, "url": "https://europepmc.org/article/MED/30564495", "status": 200, "content_type": "text/html;charset=UTF-8", "text": "Europe PMC Europe PMC 1 Sign in | Create an account https://orcid.org https://plus.europepmc.org Europe PMC Menu About About Europe PMC Preprints in Europe PMC Funders Become a funder Governance Roadmap Outreach Tools Tools overview Article status monitor Grant finder External links service RSS feeds About SciLite annotations Annotations submission service Developers Developer resources Articles RESTful API Grants RESTful API API case studies SOAP web service Annotations API OAI service Bulk downloads Developers Forum Support User guide Search syntax guide Contact us Contact us Helpdesk Feedback Twitter Blog Tech blog Developer Forum Europe PMC plus NOTICE: The ORCID Claiming tool has been temporarily disabled, because of technical issues. Please check back in later.", "truncated": false}
【tool:web_fetch】
{"ok": true, "url": "https://europepmc.org/article/MED/19963096", "status": 200, "content_type": "text/html;charset=UTF-8", "text": "Europe PMC Europe PMC 1 Sign in | Create an account https://orcid.org https://plus.europepmc.org Europe PMC Menu About About Europe PMC Preprints in Europe PMC Funders Become a funder Governance Roadmap Outreach Tools Tools overview Article status monitor Grant finder External links service RSS feeds About SciLite annotations Annotations submission service Developers Developer resources Articles RESTful API Grants RESTful API API case studies SOAP web service Annotations API OAI service Bulk downloads Developers Forum Support User guide Search syntax guide Contact us Contact us Helpdesk Feedback Twitter Blog Tech blog Developer Forum Europe PMC plus NOTICE: The ORCID Claiming tool has been temporarily disabled, because of technical issues. Please check back in later.", "truncated": false}
→ call web_search({"limit":5,"query":"\"24267730\" BOLERO-2 elderly patients HER2-negative hormone receptor-positive breast cancer everolimus exemestane"})
【tool:web_search】
{"ok": true, "query": "\"24267730\" BOLERO-2 elderly patients HER2-negative hormone receptor-positive breast cancer everolimus exemestane", "results": []}
→ call write_note({"tags":["knowledge","fact","method","4360dd15","clinical-trials","evidence-chain"],"text":"!! PMID 38310895 参考文献里又确认了 3 条“非原始首次报告”候选\n\n本轮的窄任务：把上一轮剩余的几个候选 PMID 继续压缩为“可排除”的类型。\n\n!! 已确认可排除\n* 19963096 — Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations.\n** 证据：Europe PMC 搜索结果直接标注为 Review，且摘要片段聚焦 temsirolimus 药代与剂量调整，不是首次原始人体试验。\n** 入口：https://e)
【tool:write_note】
{"ok": true, "path": "C:\\Users\\yh599\\Documents\\GitHub\\LLM-yh\\Sisyphus\\wiki\\tiddlers\\Iter-4360dd15-0104-three-remaining-candidates-are-not-original-first-reports.tid", "title": "Iter-4360dd15-0104-three-remaining-candidates-are-not-original-first-reports"}
【assistant】
本轮已把上轮剩余的 3 个候选 PMID 进一步压缩为**可排除项**：
- 19963096：题名与 Europe PMC 结果都明确指向 **Review / pharmacology / dosing considerations**24151517
- ：指向 **mTOR 抑制剂不良反应综述/汇总**，不是新原始试验30564495
- ：明确是 **Extension of a randomized controlled trial**，应按**延伸随访/非首次报告**处理
我也已把这轮结论写入长期记忆：
Iter-4360dd15-0104-three-remaining-candidates-are-not-original-first-reports
接下来最窄、最值得做的一步是：
**把 PMID 38310895 参考文献中剩余的“未决原始人体试验候选”逐条做最终二分：首次原始报告 vs 亚组/延伸/综述。**
<NEXT_FOCUS>下一轮把 PMID 38310895 参考文献里剩余未决 PMID 逐条判成“首次原始人体试验”或“非首次报告”，并把判据固化成可复用表格。</NEXT_FOCUS>
``